Revenue ($USD) : $1,021,805,000
R&D spend : $155,805,000.00
Employees : 2,900
Fiscal year end : 12/31/22
CEO : William Kozy (interim CEO)

Cardiac surgery and neuromodulation device company LivaNova’s former CEO Damien McDonald resigned in April, with board chair William Kozy still handling interim CEO responsibilities as of the writing of this description in early August. Mike Matson, senior research analyst at Needham & Co., noted that McDonald’s departure came after several pipeline disappointments. –CN